CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

CENTRAL RETINAL ARTERY OCCLUSION IN A YOUNG HIV-INFECTED PATIENT ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY.

PURPOSE: To report a case of central retinal artery occlusion (CRAO) in a young human immunodeficiency virus (HIV)-infected patient recently started on highly active antiretroviral therapy.

METHODS: Case report observation of a 33-year-old HIV-infected patient who developed a CRAO after starting highly active antiretroviral therapy.

RESULTS: Elevated triglycerides caused by starting highly active antiretroviral therapy preceded the development of CRAO in an HIV-infected patient.

CONCLUSION: Atherosclerotic vascular disease is an important complication of HIV therapy, which can ultimately lead to cardiovascular disease. An unusual case of a young patient developing a CRAO after the initiation of highly active antiretroviral therapy is reported. In the patient, the authors expound that elevated lipids from efavirenz/emtricitabine/tenofovir resulted in carotid atherosclerosis, ultimately leading to CRAO. Eye care providers, as well as the internal medicine colleagues, should be aware of the possibility of this devastating condition in HIV-infected patients on antiretroviral therapy.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app